Snapshot from Aug 25, 2026 at 07:00 UTC. For live data and tracking: View Live

United States & AbbVie

7 shared events · Importance 4 · Last updated Jul 29, 2026

Importance
4
Shared Events
7
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
69
Business
United States: The US is part of North America, which held the largest market share in 2025, supported by strong regulatory frameworks and advanced manufacturing.
AbbVie: AbbVie is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
20
Business
United States: The United States is the regulatory and market jurisdiction for the IPO, with the SEC and Nasdaq based there.
AbbVie: AbbVie's acquisition of Apogee Therapeutics is part of the M&A activity boosting biotech valuations and investor sentiment.
Jul 06, 2026 · 25 articles
17
Regulatory
United States: The recall affects U.S. patients and the FDA's regulatory environment; no direct economic impact on the country.
AbbVie: AbbVie now owns the brand Pred Forte, but is not directly affected by the recall of the generic version.
Jul 07, 2026 · 38 articles
14
Business
United States: The United States is the region where Roche and Nurix Therapeutics, Inc. will equally split profits and losses from the commercialization of bexobrutideg.
AbbVie: AbbVie is mentioned as a developer of an approved BTK inhibitor, Imbruvica, which is a competitor to bexobrutideg.
Jun 07, 2026 · 22 articles
7
Business
United States: Country where Palsonify is approved and where most patients reside.
AbbVie: Mentioned as part of 2026 M&A activity; acquired Apogee for $10.9B.
Jul 06, 2026 · 34 articles
7
Business
United States: The United States is the primary market for the therapies and the regulatory environment is influenced by the Trump administration's executive order.
AbbVie: AbbVie is a competitor that previously acquired KC Pharmaceuticals for up to $1.2B in 2024, highlighting industry interest in psychedelic therapies.
Jul 16, 2026 · 25 articles
0
Regulatory
AbbVie: AbbVie is expected to announce a deal with the Donald Trump administration after the holidays.
Dec 19, 2025 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States and AbbVie interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.